Flex and EGFR
	Click here to download entire interview
Track 1	FLEX study: Cetuximab and chemotherapy for non-small cell lung cancer (NSCLC)
Track 2	Current and future roles of EGFR testing and mutation analyses in NSCLC

Case Discussion 1 (from the practice of Dr Lynch)
	Click here to download entire interview
Track 1	Case discussion: A 68-year-old man who is a smoker with a history of CAD and current antiplatelet treatment with a moderately differentiated adenocarcinoma that is EGFR-positive, EGFR wild-type, RAS wild-type, TTF-1-positive, CK7-positive and CK20-positive Stage IV NSCLC
Track 2	Anticoagulation therapy and the use of bevacizumab
Track 3	First-line therapy options for bevacizumab-eligible patients with metastatic NSCLC
Track 4	Considerations for the use of a first-line cetuximab-based regimen in NSCLC
Track 5	Tolerability of cetuximab-associated skin rash
Track 6	Effect of Asian ethnicity on prognosis and response to cetuximab in FLEX
Track 7	Safety of chemotherapy/bevacizumab for patients with nonsquamous cell NSCLC and treated brain metastases: Data from ATLAS and PASSPORT
Track 8	Identification of patients with NSCLC for whom bevacizumab offers a favorable benefit-risk ratio

Case Discussion 2 (from the practice of Dr Lilenbaum)
	Click here to download entire interview
Track 1	Case discussion: A 69-year-old prior smoker with well-controlled hypertension and Stage IVA NSCLC
Track 2	Treatment after disease progression on first-line carboplatin/paclitaxel and bevacizumab
Track 3	Continuation of bevacizumab upon disease progression
Track 4	Patient preference for and tolerability of continued bevacizumab treatment
Track 5	Clinical implications of the study of maintenance pemetrexed in Stage IIIB/IV NSCLC with no progression after four cycles of platinum-based induction chemotherapy
Track 6	Potential role of nanoparticle albumin-bound (nab) paclitaxel in NSCLC

Case Discussion 3 (from the practice of Dr Bunn)
	Click here to download entire interview
Track 1	Case discussion: A 55-year-old Chinese-American man who is a physician and a never smoker with de novo Stage IV, TTF-1-positive, EGFR gene-amplified, EGFR mutation-negative, K-ras mutationpositive NSCLC
Track 2	Available technologies for the assessment of EGFR mutation
Track 3	Clinical response and tolerability of first-line carboplatin/pemetrexed with bevacizumab/cetuximab
Track 4	SWOG-S0536: A Phase II trial of carboplatin, paclitaxel, cetuximab and bevacizumab followed by cetuximab/bevacizumab in advanced NSCLC
Track 5	Metastectomy with curative intent for an isolated splenic metastasis
Track 6	Radiation therapy and cetuximab followed by lobectomy and maintenance cetuximab cetuximab/ bevacizumab
Track 7	Perspective on locoregional therapy for patients with oligometastatic NSCLC

Case Discussion 4 (from the practice of Dr Miller))
	Click here to download entire interview
Track 1	Case discussion: A woman who is a nonsmoker diagnosed with Stage IIIB, EGFR mutation-positive NSCLC with bronchoalveolar features
Track 2	Magnitude and duration of response to EGFR tyrosine kinase inhibitors (TKIs) in patients with EGFR mutations

Case Discussion 5 (from the practice of Dr Socinski))
	Click here to download entire interview
Track 1	Case discussion: A 65-year-old smoker with Stage IVA NSCLC
Track 2	Use of sunitinib in previously treated, advanced NSCLC
Track 3	Sunitinib-associated hypothyroidism
Track 4	Median number of treatment regimens administered for advanced NSCLC
Track 5	Referral of patients with lung cancer to medical oncologists
Track 6	Synergistic activity of radiation therapy and cetuximab
Track 7	Proposed addition of cetuximab to RTOG-0617: Standard versus high-dose radiation therapy with carboplatin/paclitaxel in Stage IIIA/IIIB NSCLC
Track 8	SWOG-S0533: A pilot trial of cisplatin/etoposide/radiation therapy followed by consolidation docetaxel/bevacizumab for inoperable, locally advanced Stage III NSCLC
Track 9	Potential role of maintenance therapy with targeted agents after chemoradiation therapy for Stage III NSCLC
Track 10	START: A Phase III study of the cancer vaccine Stimuvax® in unresectable Stage III NSCLC
Track 11	Role of pulmonary V20 values in planning chemoradiation treatment

Case Discussion 6 (from the practice of Dr Curran)
	Click here to download entire interview
Track 1	Case discussion: A 54-year-old woman with T2N3M0 NSCLC
Track 2	Caveats and considerations for the incorporation of cetuximab with chemoradiation therapy for Stage III NSCLC
Track 3	Obligation for expert opinion to provide available safety and efficacy information when discussing nonstandard treatments

Case Discussion 7 (from the practice of Dr Natale)
	Click here to download entire interview
Track 1	Case discussion: A 57-year-old woman who is an oligosmoker who underwent a lobectomy and mediastinal lymph node dissection for T2N1M0 ERCC1-positive NSCLC
Track 2	Cisplatin/docetaxel as adjuvant chemotherapy for NSCLC
Track 3	Influence of ERCC1 and patient preference on the choice of adjuvant chemotherapy
Track 4	Use of cisplatin/pemetrexed for disease upstaged to Stage IIIA non-small cell lung adenocarcinoma on the basis of microscopic disease in the lymph nodes
Track 5	Key clinical trials of the dual TKI vandetanib in NSCLC
Track 6	Dual targeting of VEGF and EGFR with vandetanib
Track 7	Circulating VEGF as a potential predictive biomarker of vandetanib in patients with advanced NSCLC
Track 8	Anticipated safety of bevacizumab in the adjuvant setting
Track 9	Adjuvant chemotherapy for Stage IB NSCLC tumors smaller than four centimeters
Track 10	Role of patient preference in adjuvant treatment decision-making for Stage IB NSCLC

Case Discussion 8 (from the practice of Dr Wozniak)
	Click here to download entire interview
Track 1	Case discussion: A 79-year-old woman who never smoked and presented with T2N0M0 NSCLC and underwent a right lobectomy with mediastinal lymph node sampling
Track 2	Benefits of adjuvant chemotherapy for the elderly with NSCLC
Track 3	Eligibility of patients with Stage IB NSCLC for RADIANT: Erlotinib with or without adjuvant chemotherapy